201 related articles for article (PubMed ID: 38097277)
1. Post-COVID-19 neuropsychiatric manifestations: a suggested therapeutic approach to 'long COVID' with azithromycin.
Schwartz RA; Suskind RM
Epidemiol Infect; 2023 Dec; 152():e34. PubMed ID: 38097277
[TBL] [Abstract][Full Text] [Related]
2. Neurological manifestations of long-COVID syndrome: a narrative review.
Stefanou MI; Palaiodimou L; Bakola E; Smyrnis N; Papadopoulou M; Paraskevas GP; Rizos E; Boutati E; Grigoriadis N; Krogias C; Giannopoulos S; Tsiodras S; Gaga M; Tsivgoulis G
Ther Adv Chronic Dis; 2022; 13():20406223221076890. PubMed ID: 35198136
[TBL] [Abstract][Full Text] [Related]
3. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial.
Hinks TSC; Barber VS; Black J; Dutton SJ; Jabeen M; Melhorn J; Rahman NM; Richards D; Lasserson D; Pavord ID; Bafadhel M
Trials; 2020 Aug; 21(1):718. PubMed ID: 32807209
[TBL] [Abstract][Full Text] [Related]
4. Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration.
Schwartz RA; Suskind RM
Dermatol Ther; 2020 Jul; 33(4):e13785. PubMed ID: 32510734
[TBL] [Abstract][Full Text] [Related]
5. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians.
Maury A; Lyoubi A; Peiffer-Smadja N; de Broucker T; Meppiel E
Rev Neurol (Paris); 2021; 177(1-2):51-64. PubMed ID: 33446327
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effects of azithromycin: A narrative review.
Khoshnood S; Shirani M; Dalir A; Moradi M; Haddadi MH; Sadeghifard N; Birjandi FS; Yashmi I; Heidary M
Biomed Pharmacother; 2022 Mar; 147():112682. PubMed ID: 35131658
[TBL] [Abstract][Full Text] [Related]
7. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce 'Brain Fog' and Results in Behavioral Changes that Favor Viral Survival.
Stefano GB; Ptacek R; Ptackova H; Martin A; Kream RM
Med Sci Monit; 2021 Jan; 27():e930886. PubMed ID: 33487628
[TBL] [Abstract][Full Text] [Related]
8. Neurological Sequelae of COVID-19.
Ahmad SJ; Feigen CM; Vazquez JP; Kobets AJ; Altschul DJ
J Integr Neurosci; 2022 Apr; 21(3):77. PubMed ID: 35633158
[TBL] [Abstract][Full Text] [Related]
9. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.
Khezri MR; Zolbanin NM; Ghasemnejad-Berenji M; Jafari R
Eur J Pharmacol; 2021 Aug; 905():174191. PubMed ID: 34015317
[TBL] [Abstract][Full Text] [Related]
10. Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19.
Stefano GB; Büttiker P; Weissenberger S; Ptacek R; Wang F; Esch T; Bilfinger TV; Raboch J; Kream RM
Curr Neuropharmacol; 2022; 20(6):1229-1240. PubMed ID: 34951387
[TBL] [Abstract][Full Text] [Related]
11. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.
Premraj L; Kannapadi NV; Briggs J; Seal SM; Battaglini D; Fanning J; Suen J; Robba C; Fraser J; Cho SM
J Neurol Sci; 2022 Mar; 434():120162. PubMed ID: 35121209
[TBL] [Abstract][Full Text] [Related]
12. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
Vitiello A; Ferrara F
Immunol Res; 2022 Feb; 70(1):129-133. PubMed ID: 34739696
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus infections from 2002 to 2021: neuropsychiatric manifestations.
Barthorpe A; Rogers JP
Sleep Med; 2022 Mar; 91():282-288. PubMed ID: 35221210
[TBL] [Abstract][Full Text] [Related]
14. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Gyselinck I; Liesenborghs L; Landeloos E; Belmans A; Verbeke G; Verhamme P; Vos R; Janssens W;
Trials; 2021 Feb; 22(1):126. PubMed ID: 33563325
[TBL] [Abstract][Full Text] [Related]
15. Historical Insight into Infections and Disorders Associated with Neurological and Psychiatric Sequelae Similar to Long COVID.
Stefano GB
Med Sci Monit; 2021 Feb; 27():e931447. PubMed ID: 33633106
[TBL] [Abstract][Full Text] [Related]
16. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study.
Borch L; Holm M; Knudsen M; Ellermann-Eriksen S; Hagstroem S
Eur J Pediatr; 2022 Apr; 181(4):1597-1607. PubMed ID: 35000003
[TBL] [Abstract][Full Text] [Related]
17. Editorial: The Pathogenesis of Long-Term Neuropsychiatric COVID-19 and the Role of Microglia, Mitochondria, and Persistent Neuroinflammation: A Hypothesis.
Stefano GB; Büttiker P; Weissenberger S; Martin A; Ptacek R; Kream RM
Med Sci Monit; 2021 May; 27():e933015. PubMed ID: 34016942
[TBL] [Abstract][Full Text] [Related]
18. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.
Antar AAR; Yu T; Demko ZO; Hu C; Tornheim JA; Blair PW; Thomas DL; Manabe YC
Front Immunol; 2023; 14():1147549. PubMed ID: 37187756
[TBL] [Abstract][Full Text] [Related]
19. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
Clin Microbiol Infect; 2021 Jan; 27(1):19-27. PubMed ID: 32860962
[TBL] [Abstract][Full Text] [Related]
20. Neurological associations of COVID-19.
Ellul MA; Benjamin L; Singh B; Lant S; Michael BD; Easton A; Kneen R; Defres S; Sejvar J; Solomon T
Lancet Neurol; 2020 Sep; 19(9):767-783. PubMed ID: 32622375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
